Body Protection Compound-157 (BPC-157) has similar angiogenic effects to its parent compound, which is instrumental in maintaining healthy intestinal lining and digestive function [1]
Semaglutide is marketed as Ozempic for managing blood sugar levels (with weight loss as an off-label benefit) and Wegovy for weight loss
The legal and ethical considerations surrounding research peptide use outside of formal research settings create additional complexities for potential users and healthcare providers
Study Design Type: Phase 3a, 68-week, multicenter, double-blind, placebo- and active-controlled trial Population: 3417 adults
However, a 2025 HSS Journal systematic review (544 articles screened, 36 included 35 preclinical, 1 clinical) concluded that high-quality clinical evidence remains limited and use should be approached with caution